Combination of Orphenadrine (Myonal) With Celecoxib (Celebrex)
Celecoxib and orphenadrine do not have a known direct drug–drug interaction listed in celecoxib prescribing information. [1] Combined use is generally appropriate from an interaction standpoint, but additive adverse effects are possible due to overlapping patient-risk factors and orphenadrine’s anticholinergic adverse-effect profile. [1], [2]
Medication Interaction Assessment
Celecoxib labeling describes clinically significant interactions primarily with drugs affecting CYP2C9 (celecoxib metabolism) and with specific co-medications such as other NSAIDs, anticoagulants, corticosteroids, digoxin, lithium, and methotrexate. [1] Orphenadrine is not listed as a celecoxib interaction in the provided prescribing-information interaction section. [1]
Safety Considerations Specific to Orphenadrine
Orphenadrine has mild anticholinergic activity and commonly causes adverse effects such as dizziness and drowsiness. [2] Orphenadrine can also cause mental confusion, hallucinations, agitation, constipation, urinary hesitancy or retention, and blurred vision in some patients. [2] These adverse effects may be more problematic when combined with other centrally acting drugs or in older adults. [2]
Safety Considerations Specific to Celecoxib
Celecoxib is an NSAID and carries class risks that include gastrointestinal bleeding and renal adverse effects, with risk increased by certain concomitant therapies and patient factors. [1] Celecoxib should not be combined with other NSAIDs or salicylates because of increased GI toxicity risk. [1]
Practical Co-Administration Guidance
When celecoxib and orphenadrine are used together, the main safety monitoring should focus on orphenadrine adverse effects such as sedation, dizziness, confusion, and anticholinergic effects. [2] Avoidance of alcohol and other sedating medications is recommended to reduce impairment from orphenadrine-associated drowsiness and dizziness. [2] Additional monitoring is appropriate in older adults and in patients with a history of urinary retention, glaucoma, arrhythmias, or significant cognitive vulnerability, based on the known anticholinergic adverse-effect potential of orphenadrine. [2]
Situations That Warrant Avoidance or Reassessment
Reassessment is warranted if other NSAIDs are used concurrently with celecoxib because combined NSAID or salicylate therapy is not recommended in celecoxib labeling. [1] Reassessment is warranted if significant confusion, hallucinations, severe dizziness, urinary retention, or visual symptoms occur while taking orphenadrine. [2]
Key Bottom-Line Safety Answer
Celecoxib can generally be taken with orphenadrine without a known direct interaction in celecoxib prescribing information. [1] The combination is mainly limited by orphenadrine-related anticholinergic and CNS adverse effects and by NSAID-related risks inherent to celecoxib. [1], [2]